Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., ...Daha Fazla

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.6, sa.1, ss.59-63, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.14744/ejmo.2022.78280
  • Dergi Adı: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.59-63
  • Anahtar Kelimeler: Hyperprogressive disease, immun checkpoint inhibitors, immunotherapy, PILE score
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter overall survival (OS) compared with those having a progressive disease (PD). Therefore, biomarkers are needed to differentiate HPD and PD.